drugset / Trial / NCT00008268

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

NCT00008268

Treatment

Summary

RATIONALE: Melphalan and colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood. PURPOSE: Phase II trial to study the effectiveness of melphalan combined with filgrastim in stimulating peripheral stem cells in patients who have multiple myeloma.

Timeline

Start
2000-08
Primary completion
2003-06
Completion
2003-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Melphalan Small molecule 60 mg/m2 Intravenous
Subject filgrastim Protein / enzyme biologic Subcutaneous

Indications